Avadim Technologies Engages ASGARD Partners & Co. as Merchant Banking Partner & Strategic Advisor

ASHEVILLE, NC—(Marketwired – June 16, 2017) – Avadim Technologies, Inc. (“Avadim”), the Bionome Therapies™ life sciences company, announced today the engagement of ASGARD Partners & Co. (“ASGARD”), to provide strategic and capital markets advisory services to Avadim.* Based in New York, the partners at ASGARD have collectively arranged and advised on more than $50 billion in transactions and have proven expertise across a wide spectrum of advisory services. ASGARD brings multi–functional capabilities to its clients and enables them to navigate their capital and growth decisions effectively. ASGARD also helps negotiate directly with banks and investors on behalf of their clients.

Steve Woody, CEO of Avadim Technologies, stated, “We are pleased to have retained ASGARD as our advisor, whose management team's expertise and proven track record will assist Avadim in assessing various financial options surrounding our capital structure and other issues to leverage the substantial growth we are experiencing to maximize shareholder value. Our growth trajectory has positioned our Company to evaluate several strategic options including financing opportunities and an initial public offering in the future. We look forward to working closely with the entire ASGARD team going forward.”

“Avadim's technology platform and products could have a tremendous impact on the way people treat conditions resulting from disruptions in the topical microbiome or skin function. We look forward to working with Steve Woody and his team to help devise and execute a comprehensive capital markets strategy,” said Nicholas Desjardins, Head of Advisory Services at ASGARD.

For more information, visit http://avadimtechnologies.com

Based in Asheville, North Carolina, Avadim is the Bionome Therapies™ life sciences company. Avadim has created a new health order by eradicating the existing “sick care” approach to deliver true “health care” through topical Bionome Therapies™ engineered to restore the skin's natural ecosystem — each with the potential to dramatically enhance the quality of life for a lifetime. People are accepting of today's standard of care (get sick, treat & repeat) even though it's inadequate and few companies have stepped up to challenge this simply unacceptable approach that has been in existence for decades. Avadim is the industry leader in delivering true microbiome compliance with effective outcomes. Microbiome compliance ensures the therapy does not negatively effect the colonization of the skin's microorganisms that human beings depend on to stay alive.

ASGARD is an advisory firm headquartered in New York. The firm provides strategic and financial advisory to, and makes private equity investments in, growth and middle–market companies. ASGARD believes that business is a powerful platform to change the world for the better and is committed to serving entrepreneurs and companies that share this belief. For more information about the firm, please visit https://asgardpartners.com.*

*All securities are offered through, Venture.co Brokerage Services LLC (“Venture.co”) Member: FINRA/SIPC. ASGARD Partners & Co. and Venture.co are independent and not affiliates. ASGARD Partners & Co., may be paid by Venture.co for technology, reporting, communications and administrative efforts; and several officers and employees of ASGARD Partners & Co. are registered representatives of Venture.co Brokerage Services LLC. ASGARD Partners & Co. officers and employees in their capacity as registered representatives of Venture.co Brokerage Services LLC may receive compensation from Venture.co as a result of brokerage related activity.

None of the aforementioned firms provide legal, tax or investment advice and is not authorized to do so. Information about any securities offering should not be considered complete and is qualified by the full offering documents corresponding to a particular project financing. This communication does not constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful. All communications by ASGARD Partners & Co. and Venture.co or any of its directors, officers, employees, representatives, affiliates or agents, are modified by the Terms of Use and Privacy Policy posted on the website at https://asgardpartners.com/ and http://Venture.co.